Top 5 Radiopharmaceutical Companies

Published: September 2026

Radiopharmaceuticals represent a fast-evolving and highly specialized segment within oncology precision medicine, combining the diagnostic and therapeutic potential of radioactive isotopes with molecules designed to target specific cancer-associated receptors or biological pathways. Unlike traditional cancer treatments that circulate broadly through the body, radiopharmaceuticals are designed to localize diseased tissue, allowing a more selective delivery of radiation to tumor cells while limiting exposure to healthy tissue. This targeted mechanism makes them especially valuable in cancers where conventional therapies have shown limited benefit or where patients need a more precise and personalized treatment approach.

The market is being shaped by growing clinical interest in theranostics, a model that pairs imaging and therapy using related compounds, enabling physicians to first identify eligible patients and then treat them with a matched radioactive agent. Prostate cancer has emerged as one of the most important application areas, alongside neuroendocrine tumors and other solid tumors, as developers continue to expand the use of radioligand therapies and diagnostic imaging agents. In parallel, progress in isotope supply chains, radiochemistry, linker design, and manufacturing capabilities is supporting broader commercialization. Strong momentum from pharmaceutical companies and biotechnology firms is further accelerating innovation in this field, making radiopharmaceuticals one of the most promising domains.

Roots Analysis has conducted an exhaustive study on featuring the current market landscape and future opportunities for companies engaged in healthcare, over a span of next 14 years.

Top Five Leading Radiopharmaceutical Companies

3BP Pharmaceuticals
Curium
ITM Radiopharma
Jubilant Radiopharma
Lantheus

The figure below highlights the top five radiopharmaceutical companies:

Top 5 Companies to Watch Radiopharmaceuticals Market

Interested in exploring all ~120 players developing radiopharmaceuticals, along with their recent initiatives?

Discover Below the Details on Top 5 Radiopharmaceutical Companies

Let us dive deep into the details of the top 5 radiopharmaceutical companies. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

1. 3B Pharmaceuticals

Company Overview

3B Pharmaceuticals is a pharmaceutical R&D company specializing in the development of targeted radiopharmaceutical therapeutics and diagnostics for oncology indications with high unmet medical need. The company develops peptide-based and diagnostic products and pursue R&D projects in radiopharmaceutical research and nuclear medicine applications.

3B Pharmaceuticals: Company Overview

	Company Name	Year of Establishment	Headquarters	Employees
	3B Pharmaceuticals	2008	Germany	1,001-5,000

Recent Developments

In April 2026, 3B Pharmaceuticals entered into a collaboration with TetraKit to combine 3B Pharmaceuticals drug discovery expertise with TetraKit’s proprietary radiolabeling platform. Together, they aim to develop a novel cancer treatment labeled with astatine-211, a highly promising alpha-emitting radionuclide designed for precise tumor targeting.

To know more about the recent initiatives of 3B Pharmaceuticals and other radiopharmaceutical companies, access full report.

2. Curium Pharma

Company Overview

Curium Pharma claims to be the world’s largest nuclear medicine company, driving clinical advancements through its integrated diagnostic and therapeutic radiopharmaceutical network. As per the company’s website, Curium Pharma operates close to 40 PET and SPECT radiopharmacies across North America and Europe.

Curium Pharma: Company Overview

	Company Name	Year of Establishment	Headquarters	Employees
	Curium Pharma	2017	France	1,001-5,000

Recent Developments

In June 2026, Curium Pharma announced an investment of EUR 32 million to establish a new European production line at its Saclay facility. This strategic investment aims to supply ¹⁷⁷Lu-PSMA-I&T, a targeted radioligand therapy (RLT) for patients with metastatic castration-resistant prostate cancer (mCRPC) to the European market.

To know more about Curium Pharma and other radiopharmaceutical companies, access full report.

3. ITM Radiopharma

Company Overview

ITM Radiopharma is a radiopharmaceutical biotech company specializing in the development, production, and global supply of precision diagnostics and therapeutics for hard-to-treat cancers. Notably, the company claims to posses the world’s largest production site for lutetium-177, an innovative medical isotope used in targeted cancer therapies.

ITM Radiopharma: Company Overview

	Company Name	Year of Establishment	Headquarters	Employees
	ITM Radiopharma	2004	Germany	501-1,000

Recent Developments

In June 2026, ITM Radiopharma presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, held in Los Angeles, California. The team presented Phase 3 COMPETE trial data demonstrating that a single post-treatment PET / CT scan can accurately calculate radiation doses for its radiopharmaceutical, in GEP-NETs patients. This single-timepoint approach significantly simplifies clinical workflows and reduces patient burden.

To know more about ITM Radiopharma and other radiopharmaceutical companies, access full report.

4. Jubilant Radiopharma

Company Overview

Headquartered in the US, Jubilant Radiopharma is involved in the advancement of patient care through its comprehensive diagnostic and therapeutic nuclear medicine portfolio. The company operates the second-largest radiopharmacy network in the US, manufacturing and delivering millions of radiopharmaceutical doses annually to more than 1,800 healthcare providers.

Jubilant Radiopharma: Company Overview

	Company Name	Year of Establishment	Headquarters	Employees
	Jubilant Radiopharma	2019	US	1,001-5,000

Recent Developments

In June 2026, the Jubilant Radiopharma announced a major construction milestone in the buildout of one of its new PET manufacturing facilities. The site will house critical equipment, including a cyclotron and advanced hot cells, to enhance production capacity. This progress underscores Jubilant's commitment to expanding its manufacturing network and broadening patient access to high-quality PET radiopharmaceutical services.

To know more about Jubilant Radiopharma and other radiopharmaceutical companies, access full report.

5. Lantheus

Company Overview

Lantheus is dedicated to transforming patient care through innovative diagnostic medical imaging and targeted therapeutics. With a strong portfolio in multiple fields including oncology, cardiology, and neurology, Lantheus develops and commercializes advanced products to improve disease detection, monitoring, and treatment worldwide.

Lantheus: Company Overview

	Company Name	Year of Establishment	Headquarters	Employees
	Lantheus	1956	US	501-1,000

Recent Developments

In June 2026, Lantheus participated at the Goldman Sachs 47th Annual Global Healthcare Conference, held in Miami Beach, Florida, highlighting the company’s latest radiopharmaceutical advancements and patient care solutions.

To know more about Lantheus and other radiopharmaceutical companies, access full report.

What About Other Radiopharmaceutical Companies Around the World?

The above article features the top five radiopharmaceutical companies selected from a pool of more than 120 companies that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources: